Portal de Periódicos da CAPES

Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort

2016; Elsevier BV; Volume: 365; Linguagem: Inglês

10.1016/j.jns.2016.03.050

1878-5883

Yolanda Aladro, Rodrigo Terrero, Marta Cerezo García, Ricardo Ginestal, Lucía Ayuso, Virginia Meca‐Lallana, Jorge Millán, Laura Borrego, Marisa Martínez-Ginés, Luisa Rubio, Clara de Andrés, Ambrosio Miralles, Cristina Ramírez Guijarro, Elena Rodríguez-García, José Manuel García‐Domínguez, Carmen Muñoz-Fernández, Carlos López de Silanes, Mayra Gómez‐Moreno, Israel J. Thuissard, M. Esperanza Cerdán, Itziar Palmí, Luis Felipe Díaz-Garzón, José Meca-Lallana,

Parvovirus B19 Infection Studies

Abstract Objective To estimate the seroprevalence of anti-JCV antibodies, seroconverting rates and evolution of antibody levels in a multiple sclerosis (MS) Spanish cohort. Methods Multicenter, retrospective cross-sectional and longitudinal study. The JCV seroprevalence was analyzed in 711 MS patients by using 1st (STRATIFY-1) and 2nd generation (STRATIFY-2) two-step ELISA over 2.65 (±0.97) years. Seroconversion rate was obtained over 2 samples from 314 patients, and index stability from 301 patients with 3 or more samples available. The effect of each ELISA generation, demographics, clinical characteristics and therapy on seroprevalence was assessed by logistic regression. Results The overall anti-JCV seroprevalence was 55.3% (51.6–58.9), similar across regions ( p =0.073). It increased with age ( p <0.000) and when STRATIFY-2 was used (60.5%, p =0.001). Neither sex nor immunosuppressive therapy had any influence. Yearly seroconversion rate was 7% (considering only STRATIFY-2). Serological changes were observed in 24/301 patients, 5.7% initially seropositive reverted to seronegative and 7% initially seronegative changed to seropositive and again to seronegative, all these cases had initial index values around the assay's cut-off. Conclusions JCV seroprevalence in Spanish MS patients was similar to that reported in other European populations. Changes in serostatus are not infrequent and should be considered in clinical decisions.